

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

**POLL RESULTS OF THE ANNUAL GENERAL MEETING  
HELD ON 28 MAY 2021;  
RETIREMENT OF DIRECTORS;  
AND  
CHANGE IN COMPOSITION OF THE BOARD COMMITTEES**

Reference is made to the notice of annual general meeting (the “**AGM Notice**”) of PuraPharm Corporation Limited (the “**Company**”) and the circular of the Company both dated 22 April 2021. The board of directors (the “**Board**”) of the Company is pleased to announce that at the annual general meeting held on Friday, 28 May 2021 at 2:30 p.m. (the “**AGM**”), the proposed resolutions no. 1-7 and the proposed resolutions no. 8 and 9 as set out in the AGM Notice were duly passed as ordinary resolutions and special resolutions, respectively, by the shareholders of the Company (the “**Shareholders**”) by way of poll. The poll results in respect of all the resolutions proposed at the AGM were as follows:

Ordinary Resolutions		Number of votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company (the “ <b>Directors</b> ”) and the auditors of the Company for the year ended 31 December 2020.	216,688,287 (100%)	0 (0%)
2.	(a) To re-elect Ms. Man Yee Wai, Viola as an executive Director.	216,688,287 (100%)	0 (0%)
	(b) To re-elect Dr. Norimoto Hisayoshi as an executive Director.	216,688,287 (100%)	0 (0%)
	(c) To authorise the board of Directors to fix the Directors’ remuneration.	216,688,287 (100%)	0 (0%)

Ordinary Resolutions		Number of votes (%)	
		For	Against
3.	To re-appoint Ernst & Young as auditor of the Company to hold office until conclusion of the next annual general meeting and to authorise the board of Directors to fix the auditor's remuneration.	216,688,287 (100%)	0 (0%)
4.	To give a general mandate to the Directors to buy back shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of passing of this resolution.	216,688,287 (100%)	0 (0%)
5.	To give a general mandate to the Directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	208,152,037 (96.06%)	8,536,250 (3.94%)
6.	To extend the general mandate granted to the Directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares bought back by the Company pursuant to the mandate granted by resolution 4.	216,688,287 (100%)	0 (0%)
7.	To refresh the scheme mandate limit under the share option scheme of the Company up to 10% of the total number of issued shares of the Company as at the date of passing of this resolution.	216,688,287 (100%)	0 (0%)
<b>Special Resolutions</b>			
8.	(a) The Chinese name of the Company be changed from “培力控股有限公司” to “培力農本方有限公司”; and	216,688,287 (100%)	0 (0%)
	(b) any one Director or the Company secretary of the company be authorised to at his/her discretion to implement the change of Chinese name of the Company.	216,688,287 (100%)	0 (0%)
9.	Amendment to Article 175(b) of the Articles of Association to allow dispatch of annual reports and notices of annual general meetings by electronic means.	216,687,787 (99.9998%)	500 (0.0002%)

The description of the above resolutions is by way of summary only. The full text of such resolutions appears in the AGM Notice of the Company dated 22 April 2021.

As the majority of the votes were cast in favour of the resolutions no. 1-7, the resolutions no. 1-7 were duly passed as ordinary resolutions of the Company and as more than 75% of the votes were cast in favour of resolutions no. 8-9, the resolutions no. 8-9 were duly passed as special resolutions of the Company.

As at the date of the AGM, the total number of issued shares of the Company was 394,892,941 shares, which was the total number of shares entitling the shareholders of the Company to attend and vote for or against on all the resolutions at the AGM. There were no shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and no Shareholder was required to abstain from voting at the AGM under the Listing Rules. There were no restriction on any Shareholders casting votes on any of the proposed resolutions at the AGM. No Shareholder had stated his or her intention in the circular of the Company dated 22 April 2021 to vote against or to abstain from voting on any of the resolutions at the AGM.

The Company’s Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

## **RETIREMENT OF DIRECTORS**

Upon the conclusion of the AGM:

- (i) Dr. Tsoi Kam Biu, Alvin (“**Dr. Tsoi**”) has retired as an executive Director and a member of the remuneration committee of the Board (the “**Remuneration Committee**”);
- (ii) Mr. Chan Kin Man, Eddie (“**Mr. Chan**”) has retired as a non-executive Director; and
- (iii) Dr. Chan Kin Keung, Eugene (“**Dr. Chan**”) has retired as an independent non-executive Director and the chairman of the Remuneration Committee and a member of the audit committee of the Board (the “**Audit Committee**”).

Each of Dr. Tsoi, Mr. Chan and Dr. Chan confirmed that he has no disagreement with the Board, and there are no other matters relating to his retirement that needs to be brought to the attention of the Shareholders and the Stock Exchange. Following the retirement of Dr. Tsoi as the executive Director, Dr. Tsoi is appointed as the senior adviser of the Company.

The Board would like to express its gratitude to Dr. Tsoi, Mr. Chan and Dr. Chan for their contribution to the Company during their tenure of office.

## **CHANGE IN COMPOSITION OF THE BOARD COMMITTEES**

Following the conclusion of the AGM, the Board resolved that to adopt the following changes to the composition of the Board committees with immediate effect:

1. Professor Tsui Lap Chee is appointed as a member of the Audit Committee;
2. Dr. Leung Lim Kin, Simon ceases to be a member of the Nomination Committee and is appointed as the chairman of the Remuneration Committee;
3. Mr. Chow, Stanley is appointed as a member of the Remuneration Committee; and
4. Mr. Ho Kwok Wah, George is appointed as a member of the Nomination Committee.

By Order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman and executive Director*

Hong Kong, 28 May 2021

*Following the conclusion of the AGM, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola, Mr. Cheong Shin Keong and Dr. Norimoto Hisayoshi; non-executive Director of the Company is Mr. Chow, Stanley; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*